Business Wire

Mitsubishi Chemical Corporation: Patent Pertinent to Lithium-ion Secondary Battery for Vehicles Granted

Share

Mitsubishi Chemical Corporation (“MCC”; HQ: Chiyoda-ku, Tokyo, President and Representative Director: Masayuki Waga) and MU Ionic Solutions Corporation (“MUIS”; HQ: Chiyoda-ku, Tokyo, President and Representative Director: Masaaki Tsuchiyama) announce the grant by the European Patent Office (“EPO”) of their jointly owned European patent pertaining to a lithium-ion secondary battery (European Patent Application Number: 06 83 2384.9; “the Patent”). The Patent, which relates to a lithium-ion secondary battery for vehicles, covers a combination of a nickel-containing positive electrode material, which is the standard choice in lithium-ion secondary batteries for vehicles, and an electrolyte comprising lithium difluorophosphate. The Patent, which has already been granted in Japan, US, China as well as South Korea, has now been additionally granted by the EPO with effect in Germany, where the demand for electric vehicles is increasing.

In recent years, nickel-containing positive electrode materials have been used in vehicle batteries because of their greater energy storage per unit volume when compared with other materials, and in order to achieve a higher capacity battery. The Patent offers a technology with extraordinary advantages for building batteries with a long life and high output, and in particular for a battery which is suited for quick recharging. This is a highly awaited development in terms of vehicle use, since this new technology, incorporating difluorophosphoric acid salt as the active component, is capable of improving the output characteristics of the batteries, in particular over known batteries using nickel-containing positive electrode materials, as well as the long-term retention of capacity, even after repeated charge/discharge cycles.

MCC and MUIS hold, apart from the Patent, a large number of further patents relating to materials for lithium-ion secondary batteries for vehicles. The prevalence of electric automobiles is expected to increase in the coming years across the globe, especially in Europe: this is driven not only as a solution to environmental challenges, such as the reduction of fossil fuel consumption and harmful gas emission, but also to allow a new society of next-generation mobility to be realized. MCC and MUIS will vigorously continue, in response to voracious demand, our activities as leading companies in the field of electrolytes for lithium-ion secondary batteries for vehicles, while promoting the healthy expansion of this market by means of appropriate use of intellectual property rights, thereby contributing to the realisation of a sustainable, next-generation society.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:
Public Relations and Investor Relations Office
Mitsubishi Chemical Holdings Corporation
Norihiko Urabe
Tel: [+81] (0)3-6748-7140

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The UK Chooses Bridge Over Troubled Water as the Nation’s Favourite Song of Hope in Solidarity With Refugees19.1.2026 10:00:00 EET | Press release

Simon and Garfunkel’s Bridge Over Troubled Water has been votedas the UK’s number one #HopeHit ― as part of UK for UNHCR’s ‘Hope on Repeat’ campaign, raising awareness of the hardships facing refugees across the globe this winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119165712/en/ Simon & Garfunkel's Bridge Over Troubled Water voted the UK's number one #HopeHit With 10% of the public vote, Bridge Over Troubled Water emerged as the UK’s most popular #HopeHit. Since November, the UN Refugee Agency’s national charity partner has invited people to nominate their #HopeHits - the tunes that connect us and warm our hearts as the weather gets cold. The top hit is announced today, Blue Monday, to help people get through the most depressing day of the year. The 1970 chart topper held off stiff competition from Stand By Me by Ben E King with 5.7% of the vote and Imagine by John Lennon with 5.3%. Hope on Repeat in support o

Prodalim Expands SOLOS Capabilities with New Dealcoholization Site in Spain19.1.2026 09:33:00 EET | Press release

Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its SOLOS division with the opening of a dedicated dealcoholization and aroma recovery site in Valencia, Spain. The new facility is fully operational and strengthens Prodalim’s ability to support the rapidly growing no- and low-alcohol (NoLo) beverage market across Europe. During the coming months, an additional SOLOS site in California is planned to be inaugurated, further expanding overall capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118626123/en/ Inauguration of the SOLOS Valencia Site for Advanced NoLo Solutions The global NoLo category continues to expand, driven by consumer demand for mindful drinking and healthier lifestyle choices. Industry forecasts estimate the NoLo global market at approximately USD 25 billion in 2025, with expected annual growth of 8–10% as the category expands across beers, win

ENHERTU ® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer19.1.2026 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast09 phase 3 trial presentedduring a speciallate-breaking oral session at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU in combination with pertuz

Syngenta to Address Global Agricultural Challenges at WEF, Championing AI to Empower Farmers and Create Open Technology Access19.1.2026 09:00:00 EET | Press release

As farmers globally grapple with unprecedented economic, geopolitical, and environmental pressures; the agricultural sector faces a continued contraction. An alarming decrease in active farms worldwide and rising financial distress underscore the urgent need for innovation and technology to ensure a resilient food system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118646017/en/ Jeff Rowe, Syngenta Group CEO "Farmers today are navigating one of the most complex periods in modern agriculture, facing pressures that demand urgent action and real solutions," said Jeff Rowe, CEO of Syngenta Group. "We have a critical window of opportunity to reverse troubling trends by ensuring every farmer, regardless of farm size or technical background, can access the transformative power of AI and digital tools.” “When we combine AI and digital tools with deep agricultural expertise, we unlock genuine potential to revolutionize farming.

KPMG Enters Strategic Relationship With Uniphore to Build AI Agents Powered by Industry-Specific Small Language Models19.1.2026 08:00:00 EET | Press release

Uniphore, the Business AI company, today announced a strategic relationship with KPMG LLP to operationalize AI agents across internal and client-facing workflows, supporting the firm’s continued effort to move from experimental AI pilots to production-grade deployment. As part of the collaboration, KPMG will work with Uniphore to build AI agents using Uniphore’s Business AI Cloud as a platform for agentic AI and fine-tuned small language models (SLMs), supporting clients across regulated industries including banking, insurance, energy and healthcare. Built on a sovereign, composable, and secure architecture, the platform integrates with KPMG’s existing enterprise systems and data environments, meeting governance and compliance requirements essential to regulated industries. This initiative reflects KPMG’s broader effort to equip its global workforce with AI-enabled delivery models, complementing its consulting expertise with AI-embedded execution inside core business processes. “We are

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye